标题
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
作者
关键词
-
出版物
BIODRUGS
Volume 33, Issue 1, Pages 15-32
出版商
Springer Nature
发表日期
2019-01-30
DOI
10.1007/s40259-019-00333-w
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease
- (2018) Michael D. Howell et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
- (2018) G.J. Schmieder et al. BRITISH JOURNAL OF DERMATOLOGY
- The regulation of JAKs in cytokine signaling and its breakdown in disease
- (2018) Henrik M. Hammarén et al. CYTOKINE
- Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
- (2018) Ian C. Scott et al. DRUG SAFETY
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
- (2018) Michael L. Vazquez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab: A review of its use in the treatment of atopic dermatitis
- (2018) Melinda J. Gooderham et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients
- (2018) S.-H. Loh et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Gerd R Burmester et al. LANCET
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
- (2018) Dominique Baeten et al. ANNALS OF THE RHEUMATIC DISEASES
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest
- (2017) William J. Sandborn et al. GASTROENTEROLOGY
- Immunopathogenesis of Rheumatoid Arthritis
- (2017) Gary S. Firestein et al. IMMUNITY
- Cytokines in systemic lupus erythematosus: far beyond Th1/Th2 dualism lupus: cytokine profiles
- (2017) Poliana Macedo Guimarães et al. IMMUNOLOGY AND CELL BIOLOGY
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
- (2017) Julian Panés et al. Journal of Crohns & Colitis
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
- (2017) Atli Thorarensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Pathogenesis of ankylosing spondylitis — recent advances and future directions
- (2017) Vidya Ranganathan et al. Nature Reviews Rheumatology
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
- (2017) A. J. Kivitz et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
- (2017) Ryan Ferrao et al. Frontiers in Endocrinology
- Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness
- (2017) Sara Guerreiro Castro et al. Therapeutic Advances in Musculoskeletal Disease
- Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion
- (2017) Lee A. Albacker et al. PLoS One
- Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
- (2016) Jean-Baptiste Telliez et al. ACS Chemical Biology
- Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- (2016) A Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
- (2016) R Westhovens et al. ANNALS OF THE RHEUMATIC DISEASES
- Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?
- (2016) Jonas K Eriksson et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis
- (2016) Somaiya Mateen et al. CLINICA CHIMICA ACTA
- Janus kinase inhibitors for rheumatoid arthritis
- (2016) Kunihiro Yamaoka CURRENT OPINION IN CHEMICAL BIOLOGY
- New therapies for psoriasis and psoriatic arthritis
- (2016) Christopher T. Ritchlin et al. CURRENT OPINION IN RHEUMATOLOGY
- Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1
- (2016) Jason G. Kettle et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
- (2016) Robert Bissonnette et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
- (2016) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
- (2016) L Kahl et al. LUPUS
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
- (2016) Laura C. Coates et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Sexual Dimorphism in the Th17 Signature of Ankylosing Spondylitis
- (2016) Eric Gracey et al. Arthritis & Rheumatology
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
- (2015) Mark G. Lebwohl et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Nucleotide-binding mechanisms in pseudokinases
- (2015) H. M. Hammaren et al. BIOSCIENCE REPORTS
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
- (2015) N. Punwani et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Cytokines in psoriasis
- (2015) Jaymie Baliwag et al. CYTOKINE
- Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing
- (2015) Mayte Suárez-Fariñas et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
- (2015) John S. Tokarski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
- (2015) Luc J. Farmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
- (2015) Lauren L. Levy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Editorial: Decernotinib: A Next-Generation Jakinib
- (2015) Massimo Gadina et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Methotrexate Is a JAK/STAT Pathway Inhibitor
- (2015) Sally Thomas et al. PLoS One
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
- (2014) Edward C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model
- (2014) S. Degryse et al. BLOOD
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
- (2014) Howard Sofen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
- (2014) Christel J. Menet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
- (2014) Mark G. Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events
- (2014) Koshiro Sonomoto et al. RHEUMATOLOGY
- The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels
- (2014) Pia Isomäki et al. RHEUMATOLOGY
- A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
- (2013) W.C. Ports et al. BRITISH JOURNAL OF DERMATOLOGY
- Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings
- (2013) Violeta Yu et al. EXPERIMENTAL HEMATOLOGY
- A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
- (2013) S. J. Sohn et al. JOURNAL OF IMMUNOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma
- (2013) A Bouchekioua et al. LEUKEMIA
- Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci
- (2013) Adrian Cortes et al. NATURE GENETICS
- JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations
- (2013) Yuan Ren et al. Scientific Reports
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- New insights of T cells in the pathogenesis of psoriasis
- (2012) Yihua Cai et al. Cellular & Molecular Immunology
- First-Line Therapies in Inflammatory Bowel Disease
- (2012) Marc Girardin et al. DIGESTION
- Role of type I interferons in the activation of autoreactive B cells
- (2012) Kerstin Kiefer et al. IMMUNOLOGY AND CELL BIOLOGY
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
- (2011) Claude Haan et al. CHEMISTRY & BIOLOGY
- Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility
- (2011) David M Evans et al. NATURE GENETICS
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese
- (2010) S. I. Davidson et al. ANNALS OF THE RHEUMATIC DISEASES
- Natural killer cells in human autoimmune diseases
- (2010) Nicolas Schleinitz et al. IMMUNOLOGY
- Cytokines and Other Mediators in Alopecia Areata
- (2010) Stamatis Gregoriou et al. MEDIATORS OF INFLAMMATION
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers
- (2008) E. G. Jeong et al. CLINICAL CANCER RESEARCH
- Evidence that cytokines play a role in rheumatoid arthritis
- (2008) Fionula M. Brennan et al. JOURNAL OF CLINICAL INVESTIGATION
- Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia
- (2008) Elisabetta Flex et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More